REAP‐HP survey 2020: Comparing the real‐world practice and expectation in Helicobacter pylori eradication of the Taiwanese gastroenterologists in 2015 and 2020

Abstract

Background: REAP-HP study (Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication) was the pioneer study investigating the expectation and preference of physicians across Asia-Pacific in H. pylori eradication in 2015. This study is the first follow-up study of REAP-HP in Taiwan. Aims: (1) To investigate the preference in regimens for the first-line anti-H. pylori therapy of Taiwanese gastroenterologist in 2020, (2) To survey the factor that cause the most concern when prescribing anti-H. pylori regimens in clinical practice, and (3) to compare REAP-HP survey data in 2020 and those surveyed in 2015 regarding the abovementioned end-points. Methods: A questionnaire for H. pylori eradication survey of physicians was distributed to the gastroenterologists who attended the Taiwan Digestive Disease Week 2020. Data of most commonly used first-line anti-H. pylori regimens and concerned factors when prescribing anti-H. pylori regimens between 2015 and 2020 were compared.

Cut-off value of clarithromycin resistance in the treatment ofHelicobacter pyloriinfection: how low is low?

“…In fact, it is a modified 14-day concomitant therapy without clarithromycin and metronidazole in the final 7 days. It is quite simple, and a recent real-world practice survey showed that 14-day reverse hybrid therapy was the third most commonly used anti- H. pylori regimen in Taiwan in 2020 10. Therefore, reverse hybrid therapy can be a recommended empirical treatment in areas of high or unknown clarithromycin resistance.…”